[New methods of interlaboratory monitoring of HIV-1 ELISA kits. Comparative study of 2 periods: 1/12/1988 to 15/4/1989 and 15/4/1989 to 31/8/1989. Le Groupe Retrovirus de la Societe Nationale de Transfusion Sanguine] NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[New methods of interlaboratory monitoring of HIV-1 ELISA kits. Comparative study of 2 periods: 1/12/1988 to 15/4/1989 and 15/4/1989 to 31/8/1989. Le Groupe Retrovirus de la Societe Nationale de Transfusion Sanguine]

Rev Fr Transfus Hemobiol. 1990 Jun;33(3):211-22. Unique Identifier : AIDSLINE MED/91000043
North ML; Noel L; Courouce AM

Abstract: Since december 1st 1988, the Retrovirus study Group of the French Society of Blood Transfusion has initiated a systematic multicentric control of all anti-HIV screening EIA test kits lots used by each member of the group. For this purpose a special panel (GRV) has been designed and forwarded to each laboratory. From december 1st 1988 to august 8 1989, 6 HIV-1 kits have been in use (Diagnostics Pasteur Elavia 1; Diagnostics Pasteur Rapid'Elavia; Organon Vironostika; Abbott HIV recombinant; Du Pont env 9; Wellcome Wellcozyme). The GRV panel has been run 204 times on 102 different lots in 12 laboratories. Results after 9 months show that these 6 kits almost always properly recognize the 5 HIV 1 positive samples of the panel. However they differ in their ability to recognize HIV 2 positive samples. Variations in results are observed from lot to lot as well as between the first half of this period and the second.
Keywords: AIDS Serodiagnosis/*METHODS/STANDARDS Comparative Study English Abstract *Enzyme-Linked Immunosorbent Assay France Human HIV Antibodies/*ANALYSIS HIV Antigens/IMMUNOLOGY HIV Seropositivity/*DIAGNOSIS HIV-1/*IMMUNOLOGY HIV-2/*IMMUNOLOGY Predictive Value of Tests *Reagent Kits, Diagnostic Recombinant Proteins/IMMUNOLOGY JOURNAL ARTICLEKWDaidsserodiagnosis/KWDmethods/standardscomparativestudyenglishabstractKWDenzyme-linkedimmunosorbentassayfrancehumanhivantibodies/KWDanalysishivantigens/immunologyhivseropositivity/KWDdiagnosishiv-1/KWDimmunologyhiv-2/KWDimmunologypredictivevalueoftestsKWDreagentkits,diagnosticrecombinantproteins/immunologyjournalarticle
910130
M9110585

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .